靶向CD19的CAR-T细胞治疗淋巴系统恶性肿瘤是否增加感染风险?
综述评估靶向CD19的CAR-T细胞治疗复发或难治性B细胞恶性肿瘤的感染并发症及危险因素。感染信息稀缺且受多因素影响,包括重度预处理、淋巴细胞清除化疗、细胞因子释放综合征或神经毒性及其治疗(抗IL-6抗体或皮质类固醇)。靶向非肿瘤毒性如B细胞发育不全、低丙种球蛋白血症和持续或双相血细胞减少常见。
要点
- CAR-T治疗患者感染风险受重度预处理、淋巴细胞清除化疗及CRS/ICANS管理影响。
- B细胞发育不全、低丙种球蛋白血症和持续或双相血细胞减少等靶向非肿瘤毒性常见。
- 感染并发症信息稀缺且难以解读,需综合评估多因素影响。
核心结论
- 靶向CD19的CAR-T细胞治疗淋巴系统恶性肿瘤的感染并发症信息稀缺且难以解读,多种因素影响感染发生率和结局。
研究设计与样本
- 综述评估已报告的CAR-T细胞治疗感染并发症及相关危险因素,并提出感染风险观点。
主要发现
- 感染风险增加与淋巴细胞清除化疗、细胞因子释放综合征或免疫效应细胞相关神经毒性综合征及其治疗(抗IL-6抗体或皮质类固醇)相关。
- 靶向非肿瘤毒性如B细胞发育不全、低丙种球蛋白血症和持续或双相血细胞减少常见。
- CAR-T细胞治疗通常用于重度预处理且严重免疫抑制的血液肿瘤患者。
临床怎么用
- 临床需综合评估重度预处理、淋巴细胞清除化疗及CRS/ICANS管理对感染风险的影响。
- 关注B细胞发育不全、低丙种球蛋白血症和持续或双相血细胞减少等靶向非肿瘤毒性。
局限性
- 感染并发症信息稀缺且难以解读,受多种因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapy with genetically engineered chimeric antigen receptor (CAR) T cells targeting the CD19 antigen is promising for a number of refractory or relapsed B-cell malignancies. Information on the infectious complications of this immunotherapeutic strategy is scarce and difficult to interpret, as many factors influence infection incidence and outcomes. CAR T-cell therapy is usually given to patients with haematological cancers who have been heavily pretreated and are severely immunosuppressed. Moreover, the risk of infection is increased by the administration of lymphodepleting chemotherapy before CAR T-cell infusion, and by the development of complications such as cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome, which are managed with anti-interleukin-6 antibodies, or corticosteroids, or both. On-target, off-tumour toxicities, such as B-cell aplasia, hypogammaglobulinaemia, and persistent or biphasic cytopenia, are common. In this Review, we evaluate the reported infectious complications of CAR T-cell therapy and associated risk factors and offer perspectives on its infection risk.
引用
- Gudiol C, Lewis RE, Strati P, et al. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? Lancet Haematol. 2021. PMID: 33460558. doi:10.1016/S2352-3026(20)30376-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。